Business Context and Reporting Period
This Form 8-K Current Report was filed by Pavmed Inc. on August 8, 2017, covering events occurring on August 3 and August 4, 2017. The filing details a private placement equity offering, the appointment of a new director, and the authorization of a new class of convertible preferred stock.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $500,000 received from the sale of 125,000 Units.
- Offering Price: $4.00 per Unit.
- Capital Structure: Each Unit consists of one share of Series A-1 Convertible Preferred Stock and one Series A-1 Warrant.
- Dividend Rate: Series A-1 Preferred Stock accrues cumulative dividends at 8% per annum, compounding quarterly.
- Commissions: No commissions or compensation were paid in connection with the sale.
Material Changes and New Agreements
The company entered into a Securities Purchase Agreement and a Registration Rights Agreement with investors. Under the Registration Rights Agreement, Pavmed Inc. is obligated to file a registration statement within 60 days of the closing date (August 4, 2017) and use commercially reasonable best efforts to have it declared effective within 150 days. Additionally, the company filed a Certificate of Designation to authorize the Series A-1 Convertible Preferred Stock, which grants holders liquidation preferences senior to common stock and specific protective voting rights regarding charter amendments.
Outlook, Management Commentary, and Risks
- Warrant Terms: Series A-1 Warrants are exercisable at $6.67 per share until April 30, 2024. They can be exchanged for four Series X Warrants (exercisable at $6.00 per share).
- Redemption Risk: The company may redeem Series X Warrants at $0.01 per warrant after April 30, 2019, if the common stock volume-weighted average price exceeds $18.00 for 20 of 30 trading days.
- Board Appointment: Dr. David S. Battleman was appointed to the Board of Directors on August 3, 2017, pursuant to a prior agreement with Scopia Holdings LLC.
- Liquidity and Registration: The securities were sold in a private placement under Section 4(a)(2) and Rule 506 exemptions. Future resale depends on the effectiveness of the registration statement.
Investor Verification Checklist
- Verify the effectiveness of the Registration Statement required to be filed within 60 days of August 4, 2017.
- Confirm the dilution impact of the 8% cumulative dividend compounding on the Series A-1 Preferred Stock.
- Review the specific terms of the Series X Warrants referenced in the February 1, 2017 Form 8-K.
- Monitor the company's ability to meet the redemption trigger price of $18.00 for common stock to avoid warrant redemption.
- Check for any subsequent closings under the $600,000 aggregate offering limit.